P2.13-36 Analysis of CDK4/6 Pathway Activity in Lung Adenocarcinoma Patients With Oncogenic Driver Mutations in China

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1431
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.13-11 EGFR Amplification and Sensitizing Mutations Correlates With Survival From Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP¶)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.09-14 Analysis of Real-Word Mutations of Lung Cancer Driver Genes in 3081 Patients From China

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P001 Discrepancy of Oncogenic Mutations in Bone Metastasis Derived From Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK Among Treatment-Naïve Patients With Advanced Lung Adenocarcinoma

PLoS ONE
Multidisciplinary
2016English

Unique Prevalence of Oncogenic Genetic Alterations in Young Patients With Lung Adenocarcinoma

Cancer
Cancer ResearchOncology
2017English

P3.13-27 Clinical Outcomes of Patients With Lung Adenocarcinoma Harboring Concomitant Driver Mutations in a Brazilian Cancer Center

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinically Significant Mutations in HIV-infected Patients With Lung Adenocarcinoma

British Journal of Cancer
Cancer ResearchOncology
2017English

Targeting CDK4/6 in Patients With Cancer

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2016English

Common Driver Mutations and Smoking History Affect Tumor Mutation Burden in Lung Adenocarcinoma

Journal of Surgical Research
Surgery
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy